OnKure Therapeutics, Inc. (OKUR) NASDAQ
4.48
-0.13(-2.82%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.48
-0.13(-2.82%)
Currency In USD
Address
6707 Winchester Circle
Boulder, CO 80301
United States of America (the)
Phone
720 307 2892
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
April 08, 2021
| Name | Title | Pay | Year Born |
| Nicholas A. Saccomano | President, Chief Executive Officer & Director | 741,743 | 1959 |
| Jason A. Leverone | Chief Financial Officer | 565,258 | 1974 |
| Samuel Agresta | Chief Medical Officer | 650,371 | 1973 |
| Dylan Hartley | Chief Scientific Officer | 0 | 1969 |
| James Blake | Senior Vice President of Computational Drug Discovery | 0 | N/A |
| Kevin S. Litwiler | Senior Vice President of DMPK & Clinical Pharmacology | 0 | N/A |
| Mark L. Boys | Senior Vice President of Discovery Chemistry | 0 | N/A |
| Rogan Nunn | General Counsel & Secretary | 0 | N/A |
| Roberta Alton | Senior VP of Clinical Operations | 0 | N/A |
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.